In contrast, responders with CRP < 1 mg/L have not only inhibition of immunometabolic pathways but also activation of the oxytocin signalling pathway, which has several anti-inflammatory properties and has been investigated as a potential therapeutic target in depression [53]. The gene discussed is CRP; the disease is depressive disorder.